No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
HK Stock MarketDetailed Quotes
01530 3SBIO
- 6.270
- -0.040-0.63%
Market Closed Jun 14 16:08 CST
15.29BMarket Cap8.94P/E (TTM)
6.420High6.260Low5.19MVolume6.260Open6.310Pre Close32.81MTurnover0.21%Turnover Ratio8.94P/E (Static)2.44BShares7.97052wk High0.99P/B15.29BFloat Cap4.91052wk Low0.10Dividend TTM2.44BShs Float22.882Historical High0.100Dividend LFY2.54%Amplitude4.420Historical Low6.317Avg Price500Lot Size1.59%Div YieldTTM1.59%Div Yield LFY
Intraday
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
On June 14th, 3sbio (01530.HK) spent HKD 3.159 million to repurchase 500,000 shares.
On June 14th, 3sbio (01530.HK) announced the repurchase of 500,000 shares for HKD 3.159 million.
On June 13, 3sbio (01530) spent approximately 3.7876 million Hong Kong dollars to repurchase 600,000 shares.
3sbio (01530) announced that it will spend approximately HKD 3.7876 million to repurchase 600,000 shares on 13 June 2024...
Do Its Financials Have Any Role To Play In Driving 3SBio Inc.'s (HKG:1530) Stock Up Recently?
3SBio's (HKG:1530) stock is up by a considerable 19% over the past three months. We wonder if and what role the company's financials play in that price change as a company's long-term fundamentals u
3sbio (01530.HK) repurchased 809,000 shares on June 11th, spending HKD 4.97 million.
On June 11th, 3sbio (01530.HK) announced that it had spent HKD 4.97 million to repurchase 809,000 shares.
3sbio (01530.HK) spent HKD 7,459,600 on June 7th to repurchase 1,183,000 shares.
On June 7th, GenScript Biotech Corporation (01530.HK) announced that they spent HKD 7.4596 million to repurchase 1.183 million shares.
3sbio (01530) repurchased 500,000 shares on June 5th for a cost of HKD 3.1994 million.
3sbio (01530) announced that it will spend HKD 3,199,400 to buy back 500,000 shares on June 5, 2024.
Comments
3SBio Inc.'s lower P/E ratio is due to its forecasted growth being less than the wider market. The potential for earnings improvement may not justify a higher P/E ratio, forming a barrier for the share price.
Investors Don't See Light At End Of 3SBio Inc.'s (HKG:1530) Tunnel 1
Despite a recent drop, 3SBio's strong financials and high ROE could boost stock value long term. Significant earnings growth due to substantial profit reinvestment, though future growth may slow.
Analyst indicates that the investment risk in 3SBio is kept in check by net cash and EBIT growth. Even though managing debt could be challenging as free cash flow was only 46% of EBIT recently, the company's financials are still strong.
3SBio, with EPS growth and increased EBIT margins, is defined as a growing business. High level of insider ownership is deemed positive, aligning with shareholders' interests. Yet, the market valuation of it remains unanalysed.
Despite positive revenue and earnings growth, 3SBio's falling share price signals potential lack of investor faith or unfulfilled market expectations.
Read more
Analysis
Price Target
No Data
Heat List
HK
Overall
Symbol
Latest Price
%Chg